PortfoliosLab logoPortfoliosLab logo
ESLOY vs. NVS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ESLOY vs. NVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Essilor International SA (ESLOY) and Novartis AG (NVS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ESLOY achieves a -36.56% return, which is significantly lower than NVS's 7.37% return. Over the past 10 years, ESLOY has underperformed NVS with an annualized return of 5.92%, while NVS has yielded a comparatively higher 9.84% annualized return.


ESLOY

1D
-0.92%
1M
-1.41%
YTD
-36.56%
6M
-44.28%
1Y
-27.89%
3Y*
4.31%
5Y*
4.22%
10Y*
5.92%

NVS

1D
0.13%
1M
-0.66%
YTD
7.37%
6M
10.70%
1Y
27.68%
3Y*
17.23%
5Y*
14.04%
10Y*
9.84%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ESLOY vs. NVS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ESLOY
Essilor International SA
-36.56%33.44%22.45%12.96%-13.84%38.51%2.43%23.58%-7.18%26.94%
NVS
Novartis AG
7.37%46.95%0.02%16.14%8.06%-3.65%3.34%13.92%5.95%19.42%

Correlation

The correlation between ESLOY and NVS is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (10Y)
Calculated over the trailing 10-year period

0.36

Correlation (All Time)
Calculated using the full available price history since Jul 16, 2007

0.40

Fundamentals

Market Cap

ESLOY:

$92.20B

NVS:

$275.25B

EPS

ESLOY:

$5.01

NVS:

$6.99

PE Ratio

ESLOY:

19.60

NVS:

20.55

PEG Ratio

ESLOY:

1.65

NVS:

1.39

PS Ratio

ESLOY:

1.67

NVS:

4.96

PB Ratio

ESLOY:

2.37

NVS:

7.15

Total Revenue (TTM)

ESLOY:

$54.89B

NVS:

$56.05B

Gross Profit (TTM)

ESLOY:

$33.87B

NVS:

$42.19B

EBITDA (TTM)

ESLOY:

$12.51B

NVS:

$22.40B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ESLOY vs. NVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ESLOY
ESLOY Risk / Return Rank: 1111
Overall Rank
ESLOY Sharpe Ratio Rank: 77
Sharpe Ratio Rank
ESLOY Sortino Ratio Rank: 88
Sortino Ratio Rank
ESLOY Omega Ratio Rank: 99
Omega Ratio Rank
ESLOY Calmar Ratio Rank: 1919
Calmar Ratio Rank
ESLOY Martin Ratio Rank: 1212
Martin Ratio Rank

NVS
NVS Risk / Return Rank: 7575
Overall Rank
NVS Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
NVS Sortino Ratio Rank: 7373
Sortino Ratio Rank
NVS Omega Ratio Rank: 7171
Omega Ratio Rank
NVS Calmar Ratio Rank: 7676
Calmar Ratio Rank
NVS Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ESLOY vs. NVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Essilor International SA (ESLOY) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ESLOYNVSDifference

Sharpe ratio

Return per unit of total volatility

-0.86

1.37

-2.23

Sortino ratio

Return per unit of downside risk

-1.26

1.94

-3.20

Omega ratio

Gain probability vs. loss probability

0.85

1.24

-0.39

Calmar ratio

Return relative to maximum drawdown

-0.61

2.20

-2.80

Martin ratio

Return relative to average drawdown

-1.27

5.52

-6.79

ESLOY vs. NVS - Sharpe Ratio Comparison

The current ESLOY Sharpe Ratio is -0.86, which is lower than the NVS Sharpe Ratio of 1.37. The chart below compares the historical Sharpe Ratios of ESLOY and NVS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ESLOYNVSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.86

1.37

-2.23

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.15

0.75

-0.60

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.22

0.50

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

0.13

0.42

-0.29

Drawdowns

ESLOY vs. NVS - Drawdown Comparison

The maximum ESLOY drawdown since its inception was -74.27%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for ESLOY and NVS.


Loading charts...

Drawdown Indicators


ESLOYNVSDifference

Max Drawdown

Largest peak-to-trough decline

-74.27%

-42.10%

-32.17%

Max Drawdown (1Y)

Largest decline over 1 year

-46.23%

-12.65%

-33.58%

Max Drawdown (3Y)

Largest decline over 3 years

-46.23%

-19.95%

-26.28%

Max Drawdown (5Y)

Largest decline over 5 years

-46.23%

-20.42%

-25.81%

Max Drawdown (10Y)

Largest decline over 10 years

-46.23%

-26.03%

-20.20%

Current Drawdown

Current decline from peak

-45.86%

-12.21%

-33.65%

Average Drawdown

Average peak-to-trough decline

-21.00%

-10.93%

-10.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.04%

5.03%

+17.01%

Volatility

ESLOY vs. NVS - Volatility Comparison

Essilor International SA (ESLOY) has a higher volatility of 6.79% compared to Novartis AG (NVS) at 5.62%. This indicates that ESLOY's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ESLOYNVSDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.79%

5.62%

+1.17%

Volatility (6M)

Calculated over the trailing 6-month period

25.90%

14.25%

+11.65%

Volatility (1Y)

Calculated over the trailing 1-year period

32.55%

20.28%

+12.27%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.16%

18.78%

+9.38%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

27.16%

19.59%

+7.57%

Dividends

ESLOY vs. NVS - Dividend Comparison

ESLOY's dividend yield for the trailing twelve months is around 2.39%, less than NVS's 3.32% yield.


PositionTTM20252024202320222021202020192018201720162015
ESLOY
Essilor International SA
2.39%1.42%1.75%1.76%1.46%0.62%0.90%1.49%1.49%3.64%2.21%0.91%
NVS
Novartis AG
3.32%2.90%3.84%3.44%3.70%3.86%3.22%3.03%3.47%3.24%3.73%3.10%

Financials

ESLOY vs. NVS - Financials Comparison

This section allows you to compare key financial metrics between Essilor International SA and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


8.00B9.00B10.00B11.00B12.00B13.00B14.00B15.00B202120222023202420252026
14.36B
13.52B
(ESLOY) Total Revenue
(NVS) Total Revenue
Values in USD except per share items

ESLOY vs. NVS - Profitability Comparison

The chart below illustrates the profitability comparison between Essilor International SA and Novartis AG over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%75.0%202120222023202420252026
58.2%
74.4%
Portfolio components
ESLOY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Essilor International SA reported a gross profit of 8.35B and revenue of 14.36B. Therefore, the gross margin over that period was 58.2%.

NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.

ESLOY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Essilor International SA reported an operating income of 1.36B and revenue of 14.36B, resulting in an operating margin of 9.5%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.

ESLOY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Essilor International SA reported a net income of 921.13M and revenue of 14.36B, resulting in a net margin of 6.4%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.


Frequently Asked Questions


ESLOY and NVS have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ESLOY has higher volatility (6.79%) compared to NVS (5.62%). In terms of maximum drawdown, ESLOY dropped -74.27% vs NVS's -42.10%.

NVS currently has the higher Sharpe Ratio (1.37 vs -0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ESLOY and NVS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer